New Stock News | Lingkai Technology's Hong Kong IPO Prospectus Invalid, Committed to Providing Small Molecule Compound Technology and Product Solutions.

Shanghai Lingkai Technology Co., Ltd. (referred to as Lingkai Technology) submitted its Hong Kong stock prospectus on June 13, 2024, which was valid for 6 months and expired on December 13. Huatai International was the exclusive sponsor at the time of submitting the prospectus. The prospectus shows that Lingkai Technology is dedicated to providing small molecule technology and product solutions, focusing on the pharmaceutical, new materials, and new energy industries. In particular, the company is one of the few leaders in China engaged in integrated chemical synthesis solutions. According to data from Zhaoshi Consulting, Lingkai Technology ranked fifth in revenue in China in 2023, with a market share of 11.7%. Integrated chemical synthesis solutions refer to a comprehensive solution that includes engineering and process technology and equipment, which helps in the implementation and production of fine chemicals. After years of efforts, Lingkai Technology has established an advanced industrialization platform, including independently developed research and development platforms, such as the Flow Chemistry and Microchannel Technology Platform and Green Catalysis Technology Platform, as well as related technologies. The company focuses on a global technology exchange online platform for small molecule compounds called Chemenu, as well as its own production facilities, to provide solutions for small molecule compound technology and products.